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cancer
Richard Morgan1*, Angie Boxall1, Kevin J Harrington2, Guy R Simpson1, Agnieszka Michael1 and Hardev S Pandha1Abstract
Background: The HOX genes are a family of transcription factors that help to determine cell and tissue identity
during early development, and which are also over-expressed in a number of malignancies where they have been
shown to promote cell proliferation and survival. The purpose of this study was to evaluate the expression of HOX
genes in prostate cancer and to establish whether prostate cancer cells are sensitive to killing by HXR9, an inhibitor
of HOX function.
Methods: HOX function was inhibited using the HXR9 peptide. HOX gene expression was assessed by RNA
extraction from cells or tissues followed by quantitative PCR, and siRNA was used to block the expression of the
HOX target gene, cFos. In vivo modelling involved a mouse flank tumour induced by inoculation with LNCaP cells.
Results: In this study we show that the expression of HOX genes in prostate tumours is greatly increased with
respect to normal prostate tissue. Targeting the interaction between HOX proteins and their PBX cofactor induces
apoptosis in the prostate cancer derived cell lines PC3, DU145 and LNCaP, through a mechanism that involves a
rapid increase in the expression of cFos, an oncogenic transcription factor. Furthermore, disrupting HOX/PBX
binding using the HXR9 antagonist blocks the growth of LNCaP tumours in a xenograft model over an extended
period.
Conclusion: Many HOX genes are highly over-expressed in prostate cancer, and prostate cancer cells are sensitive
to killing by HXR9 both in vitro and in vivo. The HOX genes are therefore a potential therapeutic target in prostate
cancer.
Keywords: Prostate cancer, HXR9, HOX, PBXBackground
Prostate cancer is the most prevalent male malignancy
with just under one million new cases worldwide each
year [1]. Treatment pathways for this disease are re-
latively well defined and include surgery, radiotherapy
and/or hormonal therapy. While the majority of patients
with early stage disease are cured, 10-15% patient still
develop locally recurrent or metastatic disease and have
a significantly reduced survival rate [2]. Despite the gen-
eral adoption of docetaxel chemotherapy agents and
novel agents such as abiraterone [3], there is still an
urgent need to develop effective new treatments, and
therefore it is necessary to explore new target proteins
and intracellular signalling pathways.* Correspondence: r.morgan@surrey.ac.uk
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stated.Recently, considerable interest has been shown in
genes that play key roles in defining the identity of cells
and tissues in early development and which therefore
also have important regulatory roles in cell proliferation
and survival. One group of genes that fit into this cat-
egory are the HOX family of transcription factors [4].
HOX proteins are characterised in part by a highly con-
served homeodomain that mediates DNA binding, to-
gether with a defined set of co-factors that modify their
function including members of PBX family [5-7]. The
pro-proliferative and anti-apoptotic roles of some HOX
genes in development make them potential oncogenes,
and indeed there are numerous reports of HOX overex-
pression in a range of malignancies, including prostate
cancer [4,8-11]. Although definitive oncogenic roles for
some HOX genes have been described, in general studies
on the function of individual HOX genes in cancer havel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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and functional redundancy exhibited by most members
[12,13]. This functional redundancy in particular has
made the results of conventional knock-down studies
(using for example siRNA) hard to interpret. As an alter-
native approach we developed a peptide, HXR9 that acts
as a competitive antagonist of the interaction between
HOX proteins and their PBX co-factor. This interaction
is mediated by a conserved hexapeptide sequence shared
by the majority of HOX proteins, and HXR9 can globally
repress HOX function through mimicking this peptide
[14-22]. In this study we show that prostate tumours
have a highly dysregulated pattern of HOX expression
and that HXR9 induces apoptosis in prostate cancer de-
rived cell lines through a mechanism that involves a
rapid increase in expression of the cFos gene. Further-
more, HXR9 can block prostate tumour growth in vivo
for an extended period, suggesting that HXR9 or its de-
rivatives might represent a possible therapeutic option
for locally recurrent prostate cancer.
Methods
Cell lines and culture
The cell lines used in this study were DU145 (derived
from a prostate carcinoma brain metastasis) [23], PC3
(derived from a prostate adenocarcinoma bone metasta-
sis) [24], LNCaP (derived from a prostate carcinoma
lymph node metastasis)[25], and WPMY-1 (derived from
normal prostate stroma and immortalised with SV40
Large T antigen) [26]. They were obtained from the
ATCC through LGC Standards Ltd (UK), and were cul-
tured according to the instructions on the LGC Stan-
dards website.
Synthesis of HXR9 and CXR9 peptides
HXR9 is an 18 amino acid peptide consisting of the previ-
ously identified hexapeptide sequence that can bind to
PBX and nine C-terminal arginine residues (R9) that facili-
tate cell entry. The N-terminal and C-terminal amino
bonds are in the D-isomer conformation, which has previ-
ously been shown to extend the half-life of the peptide to
12 hours in human serum [19]. CXR9 is a control peptide
that includes the R9 sequence but lacks a functional hexa-
peptide sequence due to a single alanine substitution. All
peptides were synthesized using conventional column
based chemistry and purified to at least 80% (Biosynthesis
Inc, USA). The sequences of the peptides are as follows:
HXR9: WYPWMKKHHRRRRRRRRR (2700.06 Da)
CXR9: WYPAMKKHHRRRRRRRRR (2604.14 Da)
Primary prostate tumour RNA
Total RNA from prostate tumours and normal prostate
tissue was obtained from OriGene Technologies Ltd,Rockville, USA. Six normal prostate tissue samples (me-
dian age of donor 56 years, range 52–71 years), and 17
prostate tumour samples (median age of donor 60 years,
range 48–73 years) were included in the analysis. Of the
prostate tumour samples, 5 were Gleason grade 6, 8
were Gleason grade 7, 1 was Gleason grade 8, and 3
were Gleason grade 9. Reverse transcription and QPCR
were performed as described below.
RNA purification and reverse transcription
Total RNA was isolated from cells using the RNeasy
Plus Mini Kit (Qiagen) by following the manufacturer’s
protocol. The RNA was denatured by heating to 65ºC
for 5 minutes. cDNA was synthesized from RNA using
the Cloned AMV First Strand Synthesis Kit (Invitrogen)
according to the manufacturer’s instructions.
Quantitative PCR
Quantitative PCR was done using the Stratagene
MX3005P real-time PCR machine and the Brilliant
SYBR Green QPCR Master Mix (Stratagene). Oligo-
nucleotide primers were designed to facilitate the unique
amplification ofβ-actin, c-Fos, and each HOX gene. The
expression of each gene was calculated using the ΔΔCt
method.
Mice and in vivo trial
All animal experiments were conducted in accordance
with the United Kingdom Co-ordinating Committee on
Cancer Research (UKCCCR) guidelines for the Welfare
of Animals in Experimental Neoplasia [27]. The expe-
rimental protocol was approved by the University of
Surrey Animal Welfare Ethical Review Board, and by the
UK Home Office (licence number 70/7347).
Athymic nude mice were kept in positive pressure iso-
lators in 12 hour light/dark cycles and food and water
were available ad libitum. Mice were inoculated sub-
cutaneously with a suspension of 2.5 × 106 LNCaP cells
in culture media (100 μl). Once tumours reached vol-
umes of approximately 100 mm3, mice received an ini-
tial, single intratumoural dose of 100 mg/Kg CXR9 or
HXR9 dissolved in 0.1 ml PBS, with subsequent dosing
when or if the tumour reoccurred. The HXR9 and CXR9
treatment groups contained 9 and 8 mice, respectively.
The mice were monitored carefully for signs of distress,
including behavioural changes and weight loss.
Results
Multiple HOX genes are dysregulated in prostate tumours
and cell lines
Previous studies have revealed that HOX genes are gen-
erally dysregulated in malignant tissue compared to nor-
mal adult cells, and we investigated whether this is
also the case in prostate cancer. In order to do this we
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tate cancer; DU145 [23], PC3 [24] and LNCaP [25], and
a cell line derived from non-malignant prostate stromal
cells, WPMY-1 [26]. QPCR analysis of expression levels
of all 39 HOX genes shows that the tumour derived cell
lines have significantly different patterns of HOX expres-
sion compared to WMPY-1. In particular, the cancer-
derived lines all show higher expression of the HOXC
genes and of HOXB5 and HOXB7, whilst WMPY-1 ex-
presses HOX genes closer to the 5′ (posterior) end of
each HOX cluster (Figure 1).
The HOX/PBX antagonist HXR9 is cytotoxic to prostate
cancer derived cell lines
Given the elevated expression of HOX genes in both pri-
mary prostate tumours and cell lines, we assessed
whether the prostate cancer-derived cell lines LNCaP,
DU145 and PC3 were sensitive to killing by the HOX/
PBX antagonist HXR9. HXR9 is an 18 amino acid pep-
tide that can enter cells via endocytosis mediated by a
polyarginine sequence. A fluorescently labelled version
of this peptide was taken up by all of the cell lines tested
(Figure 2a), and could be detected in both the cytoplasm
and the nucleus. As a negative control, we used a second
peptide, CXR9, which is identical to HXR9 with the
exception of a single alanine substitution in the hexapep-
tide sequence. PC3 cells treated with 60 μM CXR9
for two hours do not exhibit any apparent cytotoxicity
compared to untreated cells (Figure 2b, c), whilst the sameFigure 1 HOX gene expression in prostate cancer derived cell lines an
expression of each gene was determined by semi-quantitative PCR and is s
shown are the mean of three independent experiments and the error barsconcentration of HXR9 results in extensive cell death
(Figure 2d).
The cytotoxicity of HXR9 and CXR9 was determined
for all three cancer-derived lines and the non-malignant
line WPMY-1 using an MTS assay. This revealed that
all three of the lines were sensitive to killing by HXR9,
whilst WPMY-1 cells were significantly less sensitive
(Figure 2e, f ).
HXR9 induces apoptosis in prostate cancer derived
cell lines
To further understand the mechanism of HXR9-induced
cell death, we studied the activity of caspase 3 in HXR9-
treated cells. Caspase 3 is a key component of both the
intrinsic and extrinsic apoptotic pathway, and can cleave
a group of proteins involved in cell survival and prolifer-
ation. All of the prostate cancer derived cell lines
showed a significant increase in caspase 3 activity when
treated with 60 μM HXR9 for two hours (3.7 fold
for PC3 cells and 4.8 fold for both DU145 and LNCaP
cells), whilst WPMY-1 cells do not (1.4 fold increase,
p = 0.0972). Treatment with CXR9 did not change cas-
pase 3 activity in any of the cell lines (Figure 3a).
To further explore whether HXR9 induces cell death
primarily through apoptosis, we also used a FACS based
analysis for changes in the cell membrane that are
characteristic of process and which can be detected by
fluorescently labelled Anexxin. The assay also utilises a
fluorescent DNA label (7AAD) to measure the membraned in WPMY-1, which is derived from normal prostate cells. The
hown relative to the house keeping gene GAPDH (x10000). The values
represent the standard error of the mean (SEM).
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Figure 2 Prostate cancer-derived cell lines are sensitive to killing by the HOX/PBX antagonist HXR9. (a) HXR9 enters the cytoplasm and
nuclei of PC3 cells in vitro. PC3 cells were incubated with 5 μM FITC labelled HXR9 (green) for two hours and then stained with Hoechst S769121
(a fluorescent dye staining nuclei yellow). Scale bar: 20 μm (b-d) Light micrographs of PC3 cells either untreated (b) or incubated with 60 μM
CXR9 (c) or HXR9 (d) for two hours. Scale bar: 100 μm (e) Survival curves for PC3, DU145, LNCaP and WPMY-1 cells treated with HXR9. (f) IC50
values for HXR9 treatment. The negative control peptide CXR9 was not toxic at any of the concentrations tested for any of the cell lines (i.e. the
IC50 > 100 μM). Error bars represent the SEM (n = 3), the p values are with respect to WPMY-1.
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Figure 3 HXR9 induces apoptosis in prostate cancer cells. (a) Caspase 3 activity in PC3, DU145, LNCaP and WPMY-1 cells treated with 60 μM
HXR9 or CXR9 for two hours. ‘Unt’ - untreated cells; Y axis units: relative fluorescence (b) PC3, DU145, LNCaP and WPMY-1 cells were treated with
60 μM HXR9 (HX) or CXR9 (CX) for two hours and cells were assessed for apoptosis through Annexin/7AAD staining. The % of cells in apoptosis is
shown. Cells were also treated with the Caspase inhibitor ZVAD (ZV) alone or in combination with HXR9 (HX ZV). Error bars show the SEM.
*p < 0.05, **p < 0.01 with respect to untreated cells.
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http://www.biomedcentral.com/1471-2490/14/17integrity of cells, thus allowing cells to be divided into
those undergoing early or late stage apoptosis depending
on the relative binding of the two labels (Figure 3b). All of
the cell lines tested had significantly increased levels of
apoptosis after a two hour treatment with 60 μM HXR9,
compared to CXR9 treated cells. Apoptosis was consider-
ably higher in the prostate cancer derived cell lines PC3,
DU145 and LNCaP (10.6, 8.2 and 7.9 fold, respectively)
than in WPMY-1 (3.8 fold).
To provide further confirmation that cells were under-
going apoptosis, HXR9 and CXR9 treated cells were also
treated with 50 μM Z-VAD, a caspase inhibitor that
blocks the apoptotic cascade. This caused a significant
reduction in the proportion of cells undergoing apop-
tosis (Figure 3b), with the exception of WPMY-1 cells.
HXR9 induced cell death is mediated by cFos
Previous studies have suggested that HXR9-induced
apoptosis might be mediated by the elevated expressionPC
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Figure 4 HXR9 induced apoptosis is mediated by cFos. (a) QPCR analy
and WPMY-1 cells with 60 μM HXR9 or CXR9 for two hours. ‘Unt’ – untreat
(×10,000). (b) Knock down of cFos expression using siRNA. DU145 cells wer
transfected with a control siRNA with a random sequence (‘rnd siRNA’), or
2’). Cells were also either treated with 60 μM HXR9 or CXR9, or with HXR9
s1’ or ‘HXR9 + s2’). The expression of cFos in treated cells was determined
level using western blotting (lower section). (c) The % cell survival for eac
treated cells results in a statistically significant decrease in cell death. Erro
untreated cells.of the cFos gene [19,21]. To further explore this, and de-
termine whether it is true for prostate cancer derived
cells, we used QPCR to assess the expression level of
cFos in HXR9 and CXR9 treated cells. A two hour treat-
ment with 60 μM HXR9 caused a 6.2, 10.3 and 19.1 fold
increase in cFos levels in DU145, PC3 and LNCaP cells,
respectively (Figure 4a). In contrast, no significant in-
crease was observed in WPMY-1 cells.
In order to establish whether increased cFos levels
were directly responsible for inducing cell death, we
used a siRNA knock down strategy to reduce cFos ex-
pression in HXR9 treated cells. DU145 cells were trans-
fected with a random control siRNA (rnd siRNA), or
one of two different siRNAs designed against the
cFos sequence (siRNA1/2). Pre-treatment of DU145 cells
with either of the cFos siRNAs was sufficient to block
the increase in cFos expression upon subsequent treat-
ment with HXR9, both at the mRNA and protein level
(Figure 4b). This also resulted in a significant increase inUn
t
Tra
ns
f o
nly
rn
d s
iRN
A
cF
os
 si
RN
A1
cF
os
 si
RN
A2
CX
R9
HX
R9
HX
R9
 + 
s1
HX
R9
 + 
s2
0
20
40
60
80
100
cF
os
 e
xp
re
ss
io
n
b
***
*
Protein
cFos
Actin
sis of cFos expression in response to treatment of PC3, DU145, LNCaP
ed cells; cFos expression is shown as a ratio with the β-actin gene
e incubated with transfection reagent alone (‘Transf only’), or were
with one of two siRNA targeting cFos (‘cFos siRNA 1’ and ‘cFos siRNA
in combination with one of the transfected cFos specific siRNAs (‘HXR9 +
either at the RNA level using QPCR (upper section) or at the protein
h of the treatments described in (b). Knock down of cFos in HXR9
r bars show the SEM. *p < 0.05, ***p < 0.001 with respect to
a b
CXR9 HXR9
0 3 6 10 13 17 20 24 27 31 34 38 41 45 48 52
0
5
10
HXR9
CXR9
Days post treatment
R
el
at
iv
e 
tu
m
ou
r v
ol
um
e
**
CX
R9
HX
R9
0
50
100
150
cF
os
 e
xp
re
ss
io
n
c
p=
0.
03
46
HXR9fc HXR9fc
Figure 5 HXR9 retards LNCaP tumour growth in vivo. (a) Growth curve for LNCaP tumours treated intratumorally with a single dose of HXR9
(9 mice) or CXR9 (8 mice) when the tumour volume reached 100 mm3, followed by further doses if the tumour recurred. Error bars show the
SEM. “Relative tumour volume” refers to the fold change in tumour size from the time of the first injection. (b) Top panels, sections through
LNCaP tumours from mice treated with low dose (1 mg/Kg) FITC-HXR9. Top left, fluorescent view showing HXR9-FITC distribution (green).
Top right, the same section under light microscopy. Scale bar: 100 μm. Bottom panels, sections through LNCaP tumours from mice treated with
100 mg/Kg HXR9 or CXR9. The CXR9 treated section shows highly undifferentiated tumour cells, whilst the HXR9 section shows the remains of
dead tumour cells. Scale bar: 20 μm. (c) Expression of cFos in tumours treated with HXR9 or CXR9 2 hours prior to their excision, shown as a ratio
between cFos and GAPDH transcripts detected by QPCR (x10,000).
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to 37% and 56% in cells pre-treated with cFos siRNA1
and cFos siRNA2, respectively; Figure 4c).HXR9 blocks the growth of LNCaP tumours in vivo
The sensitivity of prostate cancer derived lines to killing
by HXR9 in vitro prompted us to test whether this sensi-
tivity was also apparent in vivo. We initiated flank tu-
mours in nude mice using a subcutaneous injection of
LNCaP cells, which have been used in numerous studies
as a murine model of prostate cancer. Tumours were
injected directly with HXR9 or CXR9 once the mean
tumour volume had reached 100 mm3. After 52 days the
CXR9 injected tumours had, on average, increased in
size 8 fold, whilst the average increase in HXR9 tumours
was 1.5 fold (Figure 5a). Histological analysis of tumours
revealed that whilst CXR9 treated tumours were com-
posed principally of live, highly undifferentiated cells,
those injected with HXR9 contained relatively few cells
and were composed to a large extent of cellular debris
(Figure 5b). Treating mice with a low dose of fluores-
cently labelled HXR9 revealed a widespread take up of
the peptide by the tumour cells (Figure 5b). QPCR ana-
lysis of RNA extracted from tumours revealed that
HXR9 induces an up regulation of cFos in a similar man-
ner to that seen in vitro, suggesting that a similar mech-
anism of cell death may occur (Figure 5c).HOX genes are globally overexpressed in primary
prostate tumours
As previous studies on HOX gene expression in prostate
cancer have focused only on single or small groups of
genes, we undertook an analysis of all 39 HOX genes in
prostate tumours and normal prostate tissue. This re-
vealed a considerable over expression of many HOX
family members, albeit in a heterogeneous manner with
different HOX genes being overexpressed in different tu-
mours. Only HOXC4 and HOXC6 showed consistently
higher expression in the tumour compared to the nor-
mal prostate, with increases of 101 and 251 fold, respect-
ively (Figure 6). Taking all of the HOX genes together
also revealed a significantly higher global HOX expres-
sion in tumours (11.9 fold, Figure 6).Discussion
In this study we have shown that HOX genes are highly
deregulated in prostate tumours and in prostate cancer
derived cell lines, which concurs with the findings of a
number of previous studies [9-11]. It reveals that there is
a very high level of deregulation with the majority of
HOX genes being highly expressed in tumours but not
in normal prostate tissue. This global increase in HOX
expression makes it difficult to study those aspects of
HOX function that are redundant throughout this highly
conserved group. Here we have used HXR9, an inhibitor
p=0.007
AUC=0.906
p=0.028
AUC=0.835
p=0.022
AUC=0.564
Figure 6 HOX gene expression in normal prostate tissue and prostate tumours. The expression of each gene was determined by
semi-quantitative PCR and is shown relative to the house keeping gene GAPDH (x10000). The horizontal bar represents the mean and the error
bars represent the SEM. AUC, area under the curve from a receiver-operator characteristics analysis.
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common cofactor, PBX, to target a large subset of HOX
proteins (i.e. members of paralogue groups 1-9) [19].
HXR9 causes apoptosis in all three of the prostate
derived cells line studied, but only to a far lesser degree
in a non-malignant cell line derived from prostate stroma
(WPMY-1).
Disruption of HOX/PBX regulated transcription would
be expected to cause changes in the expression of nu-
merous target genes, and indeed previous studies have
shown this to be the case. However only one of these
targets – cFos – has been shown to be directly relevant
to the induction of apoptosis by HXR9 [19]. It was previ-
ously shown that cFos up-regulation mediated the
HXR9-induced apoptosis in melanoma B16F10 cells,
and here we show that a similar mechanism exists in the
prostate cancer-derived cell lines DU145, PC3 and
LNCaP, as siRNA knock-down of cFos can partially
rescue each of these cell lines from HXR9 –induced cell
death. Although cFos is classically considered to be an
oncogene, there are now a number of reports of it acting
as a pro-apoptotic gene [19,28-31]. Our observation that
HXR9 results in a rapid and very large increase in cFos ex-
pression indicates that the HOX/PBX dimer acts as a re-
pressor of this gene. Whilst this could be a direct result of
HOX/PBX binding to its regulatory sequences, a recent
study showed that it could also be due to the increasedtranscription of the oncogenic microRNAs miR221 and
mir222, which in turn repress cFos expression [16].
The prevalence of HOX over expression in prostate
cancer combined with the novel therapeutic mechanism
exploited by HXR9 suggest that it could be a therapeutic
approach where there is small volume, well defined dis-
ease. Local delivery of HXR9 into a range of tumours in
mice has not resulted in a local inflammatory response
[18,20,21]. Therefore delivery of HXR9 directly into the
restricted confines of a primary or locally recurrent
prostate cancer is feasible, and would not be limited due
to the risk of prostatitis. Indeed a number of studies
have evaluated intraprostatic gene therapy and oncoly-
tic viral therapy and have reported no dose-limiting
toxicity. These approaches utilised current imaging
technology to achieve the precise delivery of reagents
to small volume, well defined disease [32-34]. The ap-
plication of HXR9 may be as a primary focal therapy,
or where standard treatments approaches have failed,
for example in cases of local recurrence following rad-
ical radiotherapy. The latter group of men currently re-
ceive ablative therapy which has low efficacy and is
associated with significant toxicities [35]. In contrast
to current treatments such as cryotherapy, the lack of
inflammatory response associated with HXR9 treatment
would potentially allow multiple, sequential intratu-
moral delivery.
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The HOX genes are highly dysregulated, and generally
over-expressed in prostate cancer. Targeting the inter-
action between HOX proteins and their PBX co-factor is
a potential therapeutic strategy in this malignancy.
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